Search

Etripamil

[A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

Medrogestone

[L1118] It was never approved by the FDA.

Tegafur-uracil

[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

Fospropofol

FDA approved in December 2008. Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.

Seladelpar

[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

Gemfibrozil

[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

Remestemcel-L

[L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion.

Corticosterone

(From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)

Serine

A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.

Latiglutenase